OverviewSuggest Edit
GlaxoSmithKline is a science-led global healthcare company on a mission to help people do more, feel better and live longer. The Company has three businesses that research, develop and manufacture pharmaceutical medicines, vaccines and consumer healthcare products. GlaxoSmithKline manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health.
| Type | Public | |
| Founded | 2000 | |
| HQ | Brentford, GB | Map |
| Website | gsk.com | |
| Employee Ratings | More |
Recent NewsAll News
- GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
- GSK announces succession plan to appoint new Chairman
- Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
- GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
Key People/Management at GlaxoSmithKline
Emma Walmsley
Simon Dingemans
Hal Barron
Roger Connor
James Ford
Nick Hirons
GlaxoSmithKline Office Locations
GlaxoSmithKline Financials and Metrics
GlaxoSmithKline Revenue
| GBP | |
|---|---|
Revenue (Q1, 2018) | 7.2b |
Gross profit (Q1, 2018) | 4.8b |
Gross profit margin (Q1, 2018), % | 66.9% |
Net income (Q1, 2018) | 759.0m |
EBIT (Q1, 2018) | 1.2b |
Market capitalization (11-Jul-2018) | 101.9b |
Closing stock price (11-Jul-2018) | 41.1 |
Cash (31-Mar-2018) | 4.0b |
EV | 115.4b |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.1b | 20.5b | 21.2b | 21.4b | 20.4b | 21.7b | 23.2b | 22.7b | 26.5b | 27.9b | 30.2b |
Revenue growth, % | 17% | 8% | |||||||||
Cost of goods sold | 4.0b | 4.7b | 4.6b | 4.5b | 4.3b | 4.8b | 5.0b | 5.3b | 8.6b | 9.3b | 10.3b |
Gross profit | 14.1b | 15.8b | 16.6b | 16.9b | 16.0b | 16.9b | 18.2b | 17.4b | 17.9b | 18.6b | 19.8b |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 1.3b | 716.0m | 1.1b | 962.0m | 1.2b | 4.2b | 2.0b | 3.4b | 5.5b | 4.9b | 3.8b |
Accounts Receivable | 3.3b | 3.6b | 3.5b | 3.7b | 3.8b | 4.4b | 4.4b | 4.6b | 4.0b | 6.0b | 6.0b |
Inventories | 2.3b | 2.1b | 2.1b | 2.1b | 2.2b | 2.2b | 2.4b | 3.1b | 3.9b | 5.1b | 5.6b |
Current Assets | 11.3b | 10.0b | 10.7b | 12.6b | 13.6b | 13.2b | 11.0b | 13.6b | 15.2b | 16.7b | 15.9b |
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
|---|---|---|---|---|
Cash | 4.5b | 4.0b | 4.7b | 4.0b |
Accounts Receivable | 6.2b | 6.2b | 6.5b | 6.1b |
Inventories | 5.4b | 5.7b | 5.7b | 5.7b |
Current Assets | 16.8b | 16.4b | 17.7b | 16.4b |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.3b | 3.2b | 4.0b | 4.6b | 4.4b | 4.8b | 5.5b | 5.3b | 5.6b | 1.1b | 2.2b |
Depreciation and Amortization | 2.0b | 2.9b | |||||||||
Inventories | 70.0m | (461.0m) | |||||||||
Accounts Payable | 96.0m | 11.0m |
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
|---|---|---|---|---|
Net Income | 1.2b | 1.1b | 2.5b | 759.0m |
Cash From Operating Activities | 1.1b | 2.2b | 4.0b | 863.0m |
Purchases of PP&E | (260.0m) | (639.0m) | (1.0b) | (258.0m) |
Cash From Investing Activities | (199.0m) | (646.0m) | (1.1b) | (371.0m) |
| GBP | Y, 2018 |
|---|---|
EV/EBIT | 93 x |
EV/CFO | 133.7 x |
Debt/Equity | 4.9 x |
Debt/Assets | 0.3 x |
Financial Leverage | 15.6 x |
GlaxoSmithKline Revenue Breakdown
GlaxoSmithKline revenue breakdown by business segment: 25.7% from Consumer Healthcare, 17.1% from Vaccines and 57.2% from Global Pharmaceuticals
GlaxoSmithKline revenue breakdown by geographic segment: 59.6% from International, 37.3% from US and 3.1% from Other
GlaxoSmithKline Online and Social Media Presence
175.32k Twitter followers
GlaxoSmithKline has 175.32k Twitter Followers. The number of followers has increased 0.7% month over month and increased 2% quarter over quarter
GlaxoSmithKline Blogs
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GSK announces succession plan to appoint new Chairman
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
GlaxoSmithKline Company Life and Culture
GlaxoSmithKline Frequently Asked Questions
When was GlaxoSmithKline founded?
GlaxoSmithKline was founded in 2000.
Who are GlaxoSmithKline key executives?
GlaxoSmithKline's key executives are Emma Walmsley, Simon Dingemans and Hal Barron.
How many employees does GlaxoSmithKline have?
GlaxoSmithKline has 98,462 employees.
What is GlaxoSmithKline revenue?
Latest GlaxoSmithKline annual revenue is £30.2 b.
What is GlaxoSmithKline revenue per employee?
Latest GlaxoSmithKline revenue per employee is £306.6 k.
Who are GlaxoSmithKline competitors?
Competitors of GlaxoSmithKline include Eli Lilly, Pfizer and Merck.
Where is GlaxoSmithKline headquarters?
GlaxoSmithKline headquarters is located at 980 Great West Rd, Brentford.
Where are GlaxoSmithKline offices?
GlaxoSmithKline has an office in Brentford.
How many offices does GlaxoSmithKline have?
GlaxoSmithKline has 1 office.